Animal models for fibrotic liver diseases: What we have, what we need, and what is under development

Journal of Clinical and Translational Hepatology

Volumn 3, Issue 1, 2015, Pages 53-66

  Delire, Bénédicte ^a   Stärkel, Peter ^a,b   Leclercq, Isabelle ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Animal models; Cell tracking; Fibrosis; Hepatic stellate cell; Liver

Indexed keywords

EID: 84958184486     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2014.00035     Document Type: Review

References (126)

1. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011;25:195–206. doi: 10.1016/j.bpg.2011.02.005.
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838–851. doi: 10.1016/S0140-6736(08)60383-9.
3. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009;50:1294–1306. doi: 10.1002/hep.23123.
4. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 1990;10:56–65. doi: 10.1055/s-20081040457.
5. Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim 2010;38:167–182.
6. Starkel P, Leclercq IA. Animal models for the study of hepatic fibrosis. Best Pract Res Clin Gastroenterol 2011;25:319–333. doi: 10.1016/j.bpg.2011.02.004.
7. Mailly L, Robinet E, Meuleman P, Baumert TF, Zeisel MB. Hepatitis C virus infection and related liver disease: the quest for the best animal model. Front Microbiol 2013;4:213. doi: 10.3389/fmicb.2013.00212.
8. Iimuro Y, Ikejima K, Rose ML, Bradford BU, Thurman RG. Nimodipine, a dihydropyridine-type calcium channel blocker, prevents alcoholic hepatitis caused by chronic intragastric ethanol exposure in the rat. Hepatology 1996;24:391–397. doi: 10.1002/hep.510240217.
9. Liedtke C, Luedde T, Sauerbruch T, Scholten D, Streetz K, Tacke F, et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 2013;6:19. doi: 10.1186/1755-1536-6-19.
10. Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med 2005;117:237–250.
11. Regimbeau JM, Fuks D, Kohneh-Shahri N, Terris B, Soubrane O. Restrictive model of compensated carbon tetrachloride-induced cirrhosis in rats. World J Gastroenterol. 2008;14:6943–6947. doi: 10.3748/wjg.14.6943.
12. Nagano K, Umeda Y, Saito M, Nishizawa T, Ikawa N, Arito H, et al. Thirteenweek inhalation toxicity of carbon tetrachloride in rats and mice. J Occup Health 2007;49:249–259. doi: 10.1539/joh.49.249.
13. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 1997;94:10663–10668. doi: 10.1073/pnas.94.20.10663.
14. Hillebrandt S, Goos C, Matern S, Lammert F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 2002;123:2041–2051. doi: 10.1053/gast.2002.37069.
15. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, et al. Antifibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006;45:60–71. doi: 10.1016/j.jhep.2005.12. 025.
16. Reif S, Aeed H, Shilo Y, Reich R, Kloog Y, Kweon YO, et al. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol 2004;41:235–241. doi: 10.1016/j.jhep.2004.04. 010.
17. Salguero PR, Roderfeld M, Hemmann S, Rath T, Atanasova S, Tschuschner A, et al. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab Invest 2008;88:1192–1203. doi: 10.1038/labinvest.2008.91.
18. Li X, Benjamin IS, Alexander B. Reproducible production of thioacetamideinduced macronodular cirrhosis in the rat with no mortality. J Hepatol 2002; 36:488–493. doi: 10.1016/S0168-8278(02)00011-9.
19. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538–549. doi: 10.1172/JCI1018.
20. Yeh CN, Maitra A, Lee KF, Jan YY, Chen MF. Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 2004;25:631–636. doi: 10.1093/carcin/bgh037.
21. Yang JM, Han DW, Xie CM, Liang QC, Zhao YC, Ma XH. Endotoxins enhance hepatocarcinogenesis induced by oral intake of thioacetamide in rats. World J Gastroenterol 1998;4:128–132.
22. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008;48:858–879. doi: 10.1016/j.jhep.2008.01.008.
23. George J, Rao KR, Stern R, Chandrakasan G. Dimethylnitrosamine-induced liver injury in rats: the early deposition of collagen. Toxicology 2001;156: 129–138. doi: 10.1016/S0300-483X(00)00352-8.
24. Vesselinovitch SD. The sex-dependent difference in the development of liver tumors in mice administered dimethylnitrosamine. Cancer Res 1969; 29:1024–1027.
25. Xu J, Liu X, Koyama Y, Wang P, Lan T, Kim IG, et al. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front Pharmacol 2014;5:167. doi: 10.3389/fphar.2014.00167.
26. Zhang XJ, Katsuta Y, Akimoto T, Ohsuga M, Aramaki T, Takano T. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol 2003;39:724–730. doi: 10.1016/S01 68-8278(03)00430-6.
27. Symeonidis A, Trams EG. Morphologic and functional changes in the livers of rats after ligation or excision of the common bile duct. Am J Pathol 1957; 33:13–27.
28. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984;65:305– 311.
29. Ackermann D, Mordasini D, Cheval L, Imbert-Teboul M, Vogt B, Doucet A. Sodium retention and ascites formation in a cholestatic mice model: role of aldosterone and mineralocorticoid receptor? Hepatology 2007;46:173– 179. doi: 10.1002/hep.21699.
30. Johnstone JM, Lee EG. A quantitative assessment of the structural changes the rat’s liver following obstruction of the common bile duct. Br J Exp Pathol 1976;57:85–94.
31. Tarcin O, Basaranoglu M, Tahan V, Tahan G, Sucullu I, Yilmaz N, et al. Time course of collagen peak in bile duct-ligated rats. BMC Gastroenterol 2011; 11:45. doi: 10.1186/1471-230X-11-45.
32. Georgiev P, Jochum W, Heinrich S, Jang JH, Nocito A, Dahm F, et al. Characterization of time-related changes after experimental bile duct ligation. Br J Surg 2008;95:646–656. doi: 10.1002/bjs.6050.
33. Abdel-Aziz G, Lebeau G, Rescan PY, Clement B, Rissel M, Deugnier Y, et al. Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat. Am J Pathol. 1990;137:1333–1342.
34. Zimmermann H, Fellay M, Zimmermann A. Hepatic stellate cells (Ito cells) but not collagen IV may partly be responsible for lower portal pressure after reversing secondary biliary cirrhosis in the rat. J Hepatol 1997;26:158– 166. doi: 10.1016/S0168-8278(97)80022-0.
35. Geerts AM, Vanheule E, Praet M, Van VH, De VM, Colle I. Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. Int J Exp Pathol 2008;89: 251–263. doi: 10.1111/j.1365-2613.2008.00597.x.
36. European Association for the Study of the Liver, Beuers U, Boberg KM, Chapman RW, Chazouillères O, Invernizzi P. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51: 237–267. doi: 10.1016/j.jhep.2009.04.009.
37. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013;145:521–536. doi: 10.1053/j.gastro.2013.06. 052.
38. Fickert P, Pollheimer MJ, Beuers U, Lackner C, Hirschfield G, Housset C, et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol 2014;60:1290–1303. doi: 10.1016/j.jhep.2014.02.006.
39. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, et al. Mice with homozygous disruption of the mdr2 Pglycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994; 145:1237–1245.
40. Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, et al. Spontaneous cholecysto-and hepatolithiasis in Mdr2-/-mice: a model for low phospholipid-associated cholelithiasis. Hepatology 2004;39:117–128. doi: 10.1002/hep.20022.
41. Jacquemin E, De Vree JM, Cresteil D, Sokal EM, Sturm E, Dumont M, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001;120:1448– 1458. doi: 10.1053/gast.2001.23984.
42. Leung PS, Yang GX, Dhirapong A, Tsuneyama K, Ridgway WM, Gershwin ME. Animal models of primary biliary cirrhosis: materials and methods. Methods Mol Biol 2012;900:291–316. doi: 10.1007/978-1-60761-7204_14.
43. Concepcion AR, Medina JF. Approaches to the pathogenesis of primary biliary cirrhosis through animal models. Clin Res Hepatol Gastroenterol 2012;36:21–28. doi: 10.1016/j.clinre.2011.07.007.
44. Ueno Y, Moritoki Y, Shimosegawa T, Gershwin ME. Primary biliary cirrhosis: what we know and what we want to know about human PBC and spontaneous PBC mouse models. J Gastroenterol 2007;42:189–195. doi: 10.1007/s00535-007-2019-y.
45. Wu SJ, Yang YH, Tsuneyama K, Leung PS, Illarionov P, Gershwin ME, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology 2011;53:915–925. doi: 10.1002/hep.24113.
46. Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I, et al. Ae2a,bdeficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008;134:1482– 1493. doi: 10.1053/j.gastro.2008.02.020.
47. Plum W, Tschaharganeh DF, Kroy DC, Corsten E, Erschfeld S, Dierssen U, et al. Lack of glycoprotein 130/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis. Am J Pathol. 2010;176:2236–2246. doi: 10.2353/ajpath.2010.090469.
48. Jean PA, Bailie MB, Roth RA. 1-naphthylisothiocyanate-induced elevation of biliary glutathione. Biochem Pharmacol 1995;49:197–202. doi: 10.1016/0006-2952(94)00469-2.
49. Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 2001;167:73–81. doi: 10.1016/S0300-483X(01)00459-0.
50. Tjandra K, Sharkey KA, Swain MG. Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis. Hepatology 2000;31:280–290. doi: 10.1002/hep.510310204.
51. Sullivan BP, Weinreb PH, Violette SM, Luyendyk JP. The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis. Am J Pathol 2010;177:2837–2849. doi: 10.2353/ajpath.2010. 100425.
52. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193–2213. doi: 10.1002/hep.23584.
53. Yuksel M, Laukens D, Heindryckx F, Van VH, Geerts A, Wong FS, et al. Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis. Int J Exp Pathol 2014;95:309–320. doi: 10.1111/iep.12090.
54. Jaeckel E, Hardtke-Wolenski M, Fischer K. The benefit of animal models for autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011;25:643– 651. doi: 10.1016/j.bpg.2011.10.006.
55. Zierden M, Kuhnen E, Odenthal M, Dienes HP. Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis. Gastroenterology 2010;139:975–986.e3. doi: 10.1053/j.gastro.2010.05.075.
56. Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008;205:1409–1422. doi: 10.1084/jem.20071859.
57. Dunn MA, Rojkind M, Warren KS, Hait PK, Rifas L, Seifter S. Liver collagen synthesis in murine schistosomiasis. J Clin Invest 1977;59:666–674. doi: 10.1172/JCI108685.
58. Bartley PB, Ramm GA, Jones MK, Ruddell RG, Li Y, McManus DP. A contributory role for activated hepatic stellate cells in the dynamics of Schistosoma japonicum egg-induced fibrosis. Int J Parasitol 2006;36:993– 1001. doi: 10.1016/j.ijpara.2006.04.015.
59. Paronetto F, Popper H. Chronic liver injury induced by immunologic reactions. Cirrhosis following immunization with heterologous sera. Am J Pathol 1966;49:1087–1101.
60. Baba Y, Saeki K, Onodera T, Doi K. Serological and immunohistochemical studies on porcine-serum-induced hepatic fibrosis in rats. Exp Mol Pathol 2005;79:229–235. doi: 10.1016/j.yexmp.2005.08.007.
61. European Association for the Study of Liver, Mathurin P, Hadengue A, Bataller R, Addolorato G, Burra P, et al. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57:399–420. doi: 10.1016/j.jhep.2012.04.004.
62. Mathews S, Xu M, Wang H, Bertola A, Gao B. Animals models of gastrointestinal and liver diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges. Am J Physiol Gastrointest Liver Physiol 2014;306:G819–G823. doi: 10.1152/ajpgi.00041.2014.
63. Brandon-Warner E, Schrum LW, Schmidt CM, McKillop IH. Rodent models of alcoholic liver disease: of mice and men. Alcohol 2012;46:715–725. doi: 10.1016/j.alcohol.2012.08.004.
64. Iseri OA, Lieber CS, Gottlieb LS. The ultrastructure of fatty liver induced by prolonged ethanol ingestion. Am J Pathol 1966;48:535–555.
65. Leo MA, Lieber CS. Hepatic fibrosis after long-term administration of ethanol and moderate vitamin A supplementation in the rat. Hepatology 1983;3:1–11. doi: 10.1002/hep.1840030101.
66. Keegan A, Martini R, Batey R. Ethanol-related liver injury in the rat: a model of steatosis, inflammation and pericentral fibrosis. J Hepatol 1995;23:591– 600. doi: 10.1016/0168-8278(95)80067-0.
67. Rouach H, Fataccioli V, Gentil M, French SW, Morimoto M, Nordmann R. Effect of chronic ethanol feeding on lipid peroxidation and protein oxidation in relation to liver pathology. Hepatology 1997;25:351–355. doi: 10.1002/hep.510250216.
68. Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc 2013;8:627–637. doi: 10.1038/nprot.2013.032.
69. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592–1609. doi: 10.1053/j.gastro.2012.04.001.
70. Kucera O, Cervinkova Z. Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol 2014;20:8364–8376. doi: 10.3748/wjg.v20.i26.8364.
71. Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2012;18: 2300–2308. doi: 10.3748/wjg.v18.i19.2300.
72. Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL. Characterization of high-fat, dietinduced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci 2010;55:931–940. doi: 10.1007/s10620-009-0815-3.
73. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, et al. Lipidinduced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007;46:1392–1403. doi: 10.1002/hep.21874.
74. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008;295:G987–G995. doi: 10.1152/ajpgi.90272.2008.
75. Ghoshal AK. New insight into the biochemical pathology of liver in choline deficiency. Crit Rev Biochem Mol Biol 1995;30:263–273. doi: 10.3109/10409239509083487.
76. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004;39:1286–1296. doi: 10.1002/hep.20170.
77. Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 2003;18:1272– 1282. doi: 10.1046/j.1440-1746.2003.03198.x.
78. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004;40:47– 51. doi: 10.1016/j.jhep.2003.09.020.
79. Leclercq IA, Lebrun VA, Starkel P, Horsmans YJ. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. Lab Invest 2007;87:56–65. doi: 10.1038/labinvest.3700489.
80. Kodama Y, Kisseleva T, Iwaisako K, Miura K, Taura K, de MS, et al. c-Jun Nterminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 2009;137:1467–1477. doi: 10.1053/j.gastro.2009.06.045.
81. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008;23:1635–1648. doi: 10.1111/j.1440-1746.2008.05543.x.
82. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998;12:3182–3194. doi: 10.1101/gad.12.20.3182.
83. Nakayama H, Otabe S, Ueno T, Hirota N, Yuan X, Fukutani T, et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 2007;56:470–475. doi: 10.1016/j.metabol.2006.11.004.
84. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 2004;101:2082– 2087. doi: 10.1073/pnas.0308617100.
85. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113:1774–1783. doi: 10.1172/JCI20513.
86. Kanuri G, Bergheim I. In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD). Int J Mol Sci 2013;14:11963–11980.
87. Gupte AA, Liu JZ, Ren Y, Minze LJ, Wiles JR, Collins AR, et al. Rosiglitazone attenuates age-and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 2010;52: 2001–2011. doi: 10.1002/hep.23941.
88. Yamashita T, Murakami T, Iida M, Kuwajima M, Shima K. Leptin receptor of Zucker fatty rat performs reduced signal transduction. Diabetes 1997;46: 1077–1080. doi: 10.2337/diab.46.6.1077.
89. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997;94:2557–2562. doi: 10.1073/pnas.94.6.2557.
90. Carmiel-Haggai M, Cederbaum AI, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 2005; 19:136–138.
91. Arsov T, Silva DG, O’Bryan MK, Sainsbury A, Lee NJ, Kennedy C, et al. Fat aussie–a new Alstrom syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. Mol Endocrinol 2006;20:1610– 1622. doi: 10.1210/me.2005-0494.
92. Arsov T, Larter CZ, Nolan CJ, Petrovsky N, Goodnow CC, Teoh NC, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 2006;342:1152–1159. doi: 10.1016/j.bbrc.2006.02.032.
93. Hayashi H, Sakai T. Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol 2011;300:G729–G738. doi: 10.1152/ajpgi.00013.2011.
94. Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem Biophys Res Commun 2003;308:177–183. doi: 10.1016/S0006-291X(03)01357-3.
95. Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 2006;45:419–428. doi: 10.1016/j.jhep.2006.04.010.
96. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995;92:2572–2576. doi: 10.1073/pnas.92.7.2572.
97. Nevzorova YA, Hu W, Cubero FJ, Haas U, Freimuth J, Tacke F, et al. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochim Biophys Acta 2013;1832:1765–1775. doi: 10.1016/j.bbadis.2013.06.001.
98. Mannaerts I, Schroyen B, Verhulst S, Van LL, Schuit F, Nyssen M, et al. Gene expression profiling of early hepatic stellate cell activation reveals a role for Igfbp3 in cell migration. PloS One 2013;8:e84071. doi: 10.1371/journal.pone.0084071.
99. de MS, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 2007;132:1937–1946. doi: 10.1053/j.gastro.2007.02.033.
100. Sancho-Bru P, Bataller R, Gasull X, Colmenero J, Khurdayan V, Gual A, et al. Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. J Hepatol 2005;43:272–282. doi: 10.1016/j.jhep.2005.02.035.
101. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 2012; 142:938–946. doi: 10.1053/j.gastro.2011.12.044.
102. Dickins RA, McJunkin K, Hernando E, Premsrirut PK, Krizhanovsky V, Burgess DJ, et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet 2007;39:914–921. doi: 10.1038/ng2045.
103. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008;134: 657–667. doi: 10.1016/j.cell.2008.06.049.
104. Puche JE, Lee YA, Jiao J, Aloman C, Fiel MI, Munoz U, et al. A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology 2013;57:339–350. doi: 10.1002/hep.26053.
105. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013;4:2823. doi: 10.1038/ncomms3823.
106. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, PenzOsterreicher M, et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 2010;51:1027–1036. doi: 10.1002/hep.23368.
107. Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 2011;53: 1685–1695. doi: 10.1002/hep.24206.
108. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134:1655–1669. doi: 10.1053/j.gastro.2008.03.003.
109. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA 2012;109:9448–9453. doi: 10.1073/pnas.1201840109.
110. Issa R, Zhou X, Trim N, Millward-Sadler H, Krane S, Benyon C, et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 2003;17:47–49.
111. Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 2014;514:380–384. doi: 10.1038/nature13589.
112. Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. J Control Release 2012;161:188–197. doi: 10.1016/j.jconrel.2012.02.011.
113. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008;26:431–442. doi: 10.1038/nbt1396.
114. Narmada BC, Kang Y, Venkatraman L, Peng Q, Sakban RB, Nugraha B, et al. Hepatic stellate cell-targeted delivery of hepatocyte growth factor transgene via bile duct infusion enhances its expression at fibrotic foci to regress dimethylnitrosamine-induced liver fibrosis. Hum Gene Ther 2013;24:508– 519. doi: 10.1089/hum.2012.158.
115. Bansal R, Prakash J, Post E, Beljaars L, Schuppan D, Poelstra K. Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology 2011;54:586–596. doi: 10.1002/hep.24395.
116. Grompe M, Strom S. Mice with human livers. Gastroenterology 2013;145: 1209–1214. doi: 10.1053/j.gastro.2013.09.009.
117. Bility MT, Li F, Cheng L, Su L. Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models. J Gastroenterol Hepatol 2013;28:120–124. doi: 10.1111/jgh.12092.
118. Bility MT, Cheng L, Zhang Z, Luan Y, Li F, Chi L, et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog 2014;10:e1004032. doi: 10.1371/journal.ppat.1004032.
119. Jonker AM, Dijkhuis FW, Hardonk MJ, Moerkerk P, Ten KJ, Grond J. Immunohistochemical study of hepatic fibrosis induced in rats by multiple galactosamine injections. Hepatology 1994;19:775–781. doi: 10.1002/hep.1840190334.
120. Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol 2013;94:93–103. doi: 10.1111/iep.12008.
121. Domenicali M, Caraceni P, Giannone F, Baldassarre M, Lucchetti G, Quarta C, et al. A novel model of CCl4-induced cirrhosis with ascites in the mouse. J Hepatol 2009;51:991–999. doi: 10.1016/j.jhep.2009.09.008.
122. Jimenez W, Claria J, Arroyo V, Rodes J. Carbon tetrachloride induced cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic liver disease. J Gastroenterol Hepatol 1992;7:90–97. doi: 10.1111/j.1440-1746.1992.tb00940.x.
123. Manibusan MK, Odin M, Eastmond DA. Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2007;25:185–209. doi: 10.1080/10590500701569398.
124. Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem 2006;281:15090–15098. doi: 10.1074/jbc.M600030200.
125. Wang T, Shankar K, Ronis MJ, Mehendale HM. Potentiation of thioacetamide liver injury in diabetic rats is due to induced CYP2E1. J Pharmacol Exp Ther 2000;294:473–479.
126. Heindryckx F, Colle I, Van VH. Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol 2009;90:367–386. doi: 10.1111/j.1365-2613.2009.00656.x.